Hepatitis B News and Research

Latest Hepatitis B News and Research

Faulty genes and an autoimmune condition linked to severe COVID-19 in young, healthy people

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new research shows. Another 3.5 percent, at least, carry a specific kind of genetic mutation.

25 Sep 2020

Drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes

A group of drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes, a new study suggests.

23 Sep 2020

Bioinformatics analysis reveals genes and pathways shared in COVID-19 disease and comorbidities

Using bioinformatics approaches, researchers have identified genes and pathways shared among patients with comorbidities and having severe COVID-19. The research is published on the preprint server bioRxiv in September 2020.

23 Sep 2020

Parkinson's disease diagnosed after SARS-CoV-2

As the COVID-19 pandemic continues to spread, new and unusual chronic sequelae of the disease are cropping up in many medical practices. Now, a new case paper published in The Lancet in September 2020 describes a case of new-onset Parkinson's disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2020

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

New drug candidate suppresses SARS-CoV-2 replication

Researchers at Stanford University and Utah State University have developed a novel inhibitor of the coronavirus main protease (Mpro) that effectively suppresses the viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Testing settled solids in sewage for SARS-CoV-2 more sensitive approach than testing influent

Many studies on the containment of the ongoing COVID-19 pandemic have dealt with the possible role of wastewater in predicting and detecting future outbreaks and understanding the epidemiology of COVID-19 disease. A recent study published on the preprint server medRxiv* in September 2020 shows that solid waste in sewage is a better substrate for testing than influent.

17 Sep 2020

Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.

16 Sep 2020

Keto diet could be beneficial for elderly COVID-19 patients

A recent study by researchers at Yale School of Medicine, New York University Langone Health and Washington University School of Medicine, claims that the ketogenic diet (high fat, low carbohydrate diet) is capable of mitigating clinical outcomes of coronavirus disease 2019 (COVID-19) in elderly people by improving immune-metabolic functions and reducing inflammation. The study is currently available on the bioRxiv* preprint server.

14 Sep 2020

Potential sea animal reservoirs for coronaviruses?

The COVID-19 pandemic has focused, yet again, intense research interest on coronaviruses, due to the high toll the novel coronavirus SARS-CoV-2 has taken on human life, health, economic well-being, and social activity. A recent paper published on the server Preprints in September 2020 reviews what is known about this viral infection in water life.

13 Sep 2020

New book gives overview of viruses and how they emerge to cause pandemics

Since the novel coronavirus SARS-Cov-2 emerged late last year, it has been virtually impossible to consume any news without encountering stories about the virus and how it spreads, potential treatments, and the development of new vaccines.

11 Sep 2020

CN Bio partners with Imperial College London to uncover therapeutic targets for alcoholic hepatitis

CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems to improve the accuracy and efficiency of drug discovery, today announced a collaboration with Imperial College London, a world-class research university.

10 Sep 2020

Personalized determination of genetic factors may improve treatment for polycythaemia vera

Polycythaemia vera is a chronic malignant disease of the haematopoietic system and is treated with interferon-alpha-based drugs, in most cases with long-lasting success. However, in some cases this therapy is unsuccessful for reasons that are not yet understood.

8 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

New method offers hope to patients in critical need of kidney transplant

Kidneys from deceased donors with hepatitis C virus (HCV) infection can be safely transplanted into noninfected recipients when a regimen of direct-acting antiviral therapies is initiated as early as two days after the transplant, according to a study from Massachusetts General Hospital (MGH).

2 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

Obesity ups COVID-19 death risk by 48 percent

Now, a new study by researchers from the University of North Carolina (UNC), the World Bank, and Saudi Health Council, shows that obesity increases the risk of dying from COVID-19 by as much as 48 percent, hinting that a vaccine against the virus could be less effective in obese people.

26 Aug 2020